Dear Editor,

We describe the diagnostic characteristics of three pediatric patients with early T-cell precursor (ETP)-ALL. All three patients had hyperleukocytosis with a white blood cell (WBC) count of more than 100.0×10^9^/L, showed immunophenotypic findings consistent with ETP-ALL, and were positive for *FLT3* mutations. The clinical and laboratory findings, including immunophenotyping results ([Fig. 1](#F1){ref-type="fig"}), T-cell receptor (*TCR*) rearrangements, Fms-related tyrosine kinase 3 (*FLT3*) mutations, and karyotype results, for the three patients are summarized in [Table 1](#T1){ref-type="table"}. The aim of this report is to provide information on ETP-ALL and reveal the immunophenotypic and molecular characteristics of ETP-ALL in pediatric patients.

A 14-yr-old boy presented with dizziness, vomiting, and otalgia lasting for several weeks. Laboratory tests showed WBC count of 402.2×10^9^/L, Hb of 8.4 g/dL, and platelet count of 78×10^9^/L. A peripheral blood (PB) smear revealed a very high number of blasts (94% of nucleated elements). Bone marrow (BM) aspirates revealed 100% cellularity with 97% blasts. He received induction chemotherapy (vincristine, l-asparaginase, daunorubicin, dexamethasone, and intrathecal methotrexate) and achieved complete remission (CR).

A 12-yr-old boy presented with left tibia pain for 14 days. Laboratory tests revealed WBC count of 130.1×10^9^/L, Hb of 7.4 g/dL, and platelet count of 33×10^9^/L. A PB smear revealed that 75% of nucleated elements were leukemic blasts. BM aspirates revealed 100% cellularity with 99% blasts. After ALL induction chemotherapy, he achieved CR and received consolidation chemotherapy.

A 12-yr-old boy presented with fever, cough, and petechiae of both tibiae for several weeks. Laboratory tests revealed WBC count of 169.5×10^9^/L, Hb of 8.7 g/dL, and platelet count of 194×10^9^/L. A PB smear revealed a markedly high number of blasts (89% of nucleated elements). He achieved CR after ALL induction chemotherapy.

ETP-ALL is a T-ALL subtype with a very high risk of remission induction failure, relapse, and overall poor prognosis; it is characterized by a specific immunophenotype, i.e., CD1a(-), CD8(-), CD5 weak, with one or more stem cell or myeloid-associated markers \[[@B1][@B2]\]. Our three patients showed very similar immunophenotypic patterns, with common expression of cCD3, T-cell markers (e.g., CD2 and CD7), and stem cell or myeloid/stem cell markers (e.g., CD34 and CD117) ([Table 1](#T1){ref-type="table"}). The myeloid marker CD13 was expressed in two patients and the myeloid/monocytic marker CD64 was expressed in one patient. Although weak or negative CD5 was initially a part of the diagnostic criteria for ETP-ALL \[[@B1]\], the optimal aggregate of immunophenotypic markers for ETP leukemic cell identification is unknown. In a recent study, for example, CD4 and CD8 double negativity, in addition to CD34 or CD13/CD33 expression predicted 10 out of 13 cases with an ETP-ALL gene signature \[[@B3]\].

T-ALL shows a very high incidence of clonal rearrangements of TCR genes \[[@B4]\]. In our case series of ETP-ALL patients, *TCR* rearrangement was found in one (*TCRγ*) of the three patients, in contrast to a previous study that found *TCR* rearrangements in eight of nine ETP-ALL patients \[[@B1]\]. The development of the pro-T-cell, including the ETP stage, may be independent of *TCR* rearrangement because it is involved in the initial phase of T-cell differentiation, which is coordinated by the migration of distinct thymic microenvironments \[[@B5]\]. CD4 and CD8 double negative (DN) thymocytes can be classified into four developmental stages (DN1, 2, 3, and 4) on the basis of CD44 and CD25 expressions \[[@B6]\]. *TCR* rearrangement starts at DN2 with the *TCRδ* locus, followed by *TCRγ* and *TCRβ*, and rearrangement is completed during DN3 \[[@B7]\].

*FLT3* mutations, such as internal tandem duplications (ITDs), are the most common somatic alterations in AML and predict a poor prognosis \[[@B8]\]. *FLT3* mutations were detected in all three patients, consistent with a previous study that reported a high frequency (35%) of *FLT3* mutations in ETP-ALL and found that *FLT3* mutations are less strongly associated with *TCR* rearrangements than wild-type *FLT3* in ETP-ALL \[[@B9]\]. The coexistence of *FLT3* mutations and CD117/KIT expression in our patients was consistent with previous results that T-ALL patients with CD117/KIT expression tend to harbor *FLT3* mutations \[[@B10]\].

Although the three patients responded well to remission induction chemotherapy and have maintained CR ([Table 1](#T1){ref-type="table"}), we emphasize the need for close follow-up because ETP-ALL has a high risk of relapse, especially in children \[[@B2]\]. ETP-ALL has recently been recognized as a distinct entity within ALL; accordingly, literature on the diagnosis and treatment of ETP-ALL is limited. The morphological, immunophenotypic, and molecular characterization of three pediatric ETP-ALL patients in this study may aid in the diagnosis of this rare, but important subtype of acute leukemia.
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![Immunophenotyping of early T-cell precursor-ALL bone marrow sample (case 3). (A) CD45/SSC dot plot with the blast population highlighted. (B) FSC/SSC plot of the sample. Blasts are positive for cCD3 (C); CD13, CD117 (D); CD99 (E) and negative for CD1a (E). Please refer to [Table 1](#T1){ref-type="table"} for the immunophenptyping results of cases 1 and 2.](alm-36-384-g001){#F1}

###### Clinical and laboratory characteristics of the three patients with early T-cell precursor (ETP)-ALL at initial presentation

![](alm-36-384-i001)

  No. case   Sex/Age (yr)   Mediastinal mass   WBC count (×10^9^/L)   Immunophenotyping Positivity/Negativity                                  TCR rearrangement   FLT3 mutation   Karyotype   Treatment/Relapse-free survival                                               
  ---------- -------------- ------------------ ---------------------- ------------------------------------------------------------------------ ------------------- --------------- ----------- --------------------------------- ------------------------------------------- ---------------------------
  1          M/14           No                 402.2                  CD2, cCD3, CD7, CD13, CD34, CD99, CD117, and HLA-DR/CD1a, CD5, and CD8   No                  No              No          ITD mutation                      47,XY,+4\[5\]/46,XY\[15\]                   Chemotherapy: CR/6 months
  2          M/12           No                 130.1                  CD2, cCD3, CD7,CD34, CD64, CD99, CD117, and HLA-DR/CD1a, CD5, and CD8    No                  No              No          ITD mutation                      45,XY,del(6)(q21q23), -21\[3\]/46,XY\[9\]   Chemotherapy: CR/8 months
  3          M/12           No                 169.5                  CD2, cCD3,CD7, CD13,CD34, CD99, and CD117/CD1a, CD5, and CD8             No                  Yes             No          TKD mutation                      46,XY\[20\]                                 Chemotherapy: CR/8 months

Abbreviations: WBC, white blood cell; TCR, T cell receptor, ITD, internal tandem duplication; TKD, tyrosine kinase domain; CR, complete remission.
